Search the Community

I was reading the BSH Guidelines for the Estimation of Fetomaternal Haemorrhage, and I had a few questions: 7.2 Slide Preparation In my current workplace, we do not dilute the sample, and my previous workplace did. I could not see a significant difference on the slide that was made and found them both equally adequate, but I was wondering if other have any input on them 7.3 Controls We currently prepare the control slide a week in advance and not fix or stain them, until required for batch testing. I have checked all the slides after it had undergone AE test, and all of them had been adequate. I was wondering if there is something which we are overlooking? These were the only things that were nibbling at the back of my mind after going through the guidelines. If someone could put it to rest, I will be grateful. Bonus Question I was wondering if transfusing Rhesus D Negative pregnant women have any implication on the FMH screening/ quantification, and what they would be? Cheers, Jermin

Hi all, I'm trying to find out the similarities and differences around the world (but particularly in Europe) for guidelines related to measuring fetomaternal haemorrhages and issue of anti-D. I'm particularly interested in which countries issue anti-D and don't estimate the FMH, what formulas countries use for calculating doses, what tests different countries use, whether the FMH is measured in whole blood or packed cells, whether different countries use the 1.22 muiltiplier to account for the different sizes of red cells... Not a small list I know. I've found a few international guidelines already so here are some useful links UK guidelines for all Transfusion related things are here http://www.b-s-h.org.uk/guidelines/ Irish guideline on the use of Anti-D http://www.hse.ie/eng/about/Who/clinical/natclinprog/obsandgynaeprogramme/antidprevrhd.pdf Australian guideline on the use of anti-D https://www.ranzcog.edu.au/RANZCOG_SITE/media/DOCMAN-ARCHIVE/Guidelines for the use of Rh(D) Immunoglobulin (Anti-D) (C-Obs 6) Review November 2015.pdf Australia/New Zealand guideline on measurement of FMH https://www.anzsbt.org.au/data/documents/guidlines/ANZSBTguide_Nov02a.pdf Canadian guideline on the use of anti-D https://sogc.org/wp-content/uploads/2013/01/133E-CPG-September2003.pdf Please add links to this forum Many thanks, Katy Veale